



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> C07K 7/06, 7/08, 14/575, A61K 38/08, 38/10, 38/22, A61P 19/08, 19/10	<b>A1</b>	<b>(11) International Publication Number:</b> WO 00/58348 <b>(43) International Publication Date:</b> 5 October 2000 (05.10.00)
<b>(21) International Application Number:</b> PCT/NZ00/00038 <b>(22) International Filing Date:</b> 29 March 2000 (29.03.00)  <b>(30) Priority Data:</b> 09/280,501                      30 March 1999 (30.03.99)                      US  <b>(71) Applicant:</b> AUCKLAND UNISERVICES LIMITED [NZ/NZ]; UniServices House, 58 Symonds Street, Auckland (NZ).  <b>(72) Inventors:</b> CORNISH, Jillian; 22a Godden Crescent, Mission Bay, Auckland (NZ). REID, Ian, Reginald; 7 Maybeck Road, Mt Albert, Auckland (NZ). COOPER, Garth, James, Smith; 7 Marine Parade, Herne Bay, Auckland 2 (NZ).  <b>(74) Agents:</b> BENNETT, Michael, Roy et al.; West-Walker Ben- nett, Mobil on the Park, 157 Lambton Quay, Wellington (NZ).		<b>(81) Designated States:</b> AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> TREATMENT OF BONE DISORDERS WITH ADRENOMEDULLIN OR ADRENOMEDULLIN AGONISTS  <b>(57) Abstract</b>  A method for promoting bone growth in a patient (e.g., a mammal such as a human) said method including the step of administering a therapeutically effective amount of adrenomedullin or an adrenomedullin agonist to said patient.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TREATMENT OF BONE DISORDERS WITH ADRENOMEDULLIN  
OR ADRENOMEDULLIN AGONISTS

5

Field of the Invention

This invention relates to a method of promoting bone growth in a patient.

10

Background of the Invention

Adrenomedullin is a 52-amino acid peptide originally identified in a human pheochromocytoma. It has since been found in normal adrenal medulla, as well as other tissues such as the atria, ventricles, endothelial cells, lungs, brain and kidneys. Adrenomedullin also circulates in picomolar concentrations in both rats and man.

Several biological effects have been attributed to adrenomedullin. It has been described as a potent vasodilator, acting directly on the renal, cerebral, mesenteric, pulmonary, and systemic circulations. Administration of adrenomedullin can result in hypotension. Binding of adrenomedullin to renal tubular membranes has also been observed, and sodium, potassium, and water excretion are increased by adrenomedullin. Adrenomedullin can in addition be a bronchodilator, and it has been reported to modulate the release of pituitary and vasoactive hormones.

### Summary of the Invention

The present invention is based on the discovery that adrenomedullin and peptide fragments of adrenomedullin can stimulate proliferation of osteoblasts, which give rise to bone tissue. Accordingly, the invention provides methods for promoting bone growth, and compositions useful for promoting bone growth.

In one aspect the invention provides a method for promoting bone growth in a patient, e.g., a mammal such as a human. The method includes the step of administering a therapeutically effective amount of adrenomedullin or an adrenomedullin agonist to the patient. The patient may be suffering from a disease associated with excessive resorption or breakdown of bone tissue such as osteoporosis or Paget's disease. The patient may also be suffering from bone losses as a result of immobility, bone fractures, malignancy, endocrine disorders, autoimmune arthritis, or drug use. The patient may also be undergoing a treatment (e.g., corticosteroid treatment, bone marrow transplantation, or oophorectomy) known to result in bone loss.

In another aspect, the invention features a method for prevent or retarding the development of a bone-associated diseases in a subject, e.g. a mammalian subject such as a human. Thus, the adrenomedullin and adrenomedullin agonists described herein may be used, e.g., to prevent development of osteoporosis or Paget's disease in a subject.

A therapeutically effective amount depends upon the condition being treated, the route of administration chosen, and the specific activity of

the compound used and ultimately will be decided by the attending physician or veterinarian. In one embodiment, the adrenomedullin agonist is administered to the patient until the patient's bone mass has been  
5 restored to normal levels. Thus, the duration of the administration may be dependent upon the severity of the patient's bone loss.

The adrenomedullin or adrenomedullin agonist may be administered parenterally, e.g., administered  
10 intravenously, subcutaneously, or by implantation of a sustained release formulation. However, it will be readily appreciated by those skilled in the art that the route, such as intravenous, subcutaneous, intramuscular, intraperitoneal, enterally,  
15 transdermally, transmucously, sustained released polymer compositions (e.g., a lactide polymer or copolymer microparticle or implant), perfusion, pulmonary (e.g., inhalation), nasal, oral, etc., will vary with the condition being treated and the activity  
20 and bioavailability of the adrenomedullin or adrenomedullin agonist being used.

While it is possible for the adrenomedullin or adrenomedullin agonist to be administered as the pure or substantially pure compound, it may also be  
25 presented as a pharmaceutical formulation or preparation. The formulations to be used in the present invention, for both humans and animals, comprise any of the adrenomedullin or adrenomedullin agonists to be described below, together with one or  
30 more pharmaceutically acceptable carriers thereof, and optionally other therapeutic ingredients.

The carrier must be "acceptable" in the sense of being compatible with the active ingredient(s) of

the formulation (e.g., capable of stabilizing peptides) and not deleterious to the subject to be treated. Desirably, the formulation should not include oxidizing agents or other substances with which peptides are known to be incompatible. For example, adrenomedullin or adrenomedullin agonists in the cyclized form (e.g., internal cysteine disulfide bond) are oxidized; thus, the presence of reducing agents as excipients could lead to an opening of the cysteine disulfide bridge. On the other hand, highly oxidative conditions can lead to the formation of cysteine sulfoxide and to the oxidation of tryptophane. Consequently, it is important to carefully select the excipient. Ph is another key factor, and it may be necessary to buffer the product under slightly acidic conditions (Ph 5 to 6).

The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient(s) into association with the carrier which constitutes one or more accessory ingredients.

In general, the formulations for tablets or powders are prepared by uniformly and intimately blending the active ingredient with finely divided solid carriers, and then, if necessary, as in the case of tablets, forming the product into the desired shape and size.

Formulations suitable for parenteral (e.g., intravenous) administration, on the other hand, conveniently comprise sterile aqueous solutions of the active ingredient(s). Preferably, the solutions are isotonic with the blood of the subject to be treated.

Such formulations may be conveniently prepared by dissolving solid active ingredient(s) in water to produce an aqueous solution, and rendering said solution sterile. The formulation may be presented in  
5 unit or multi-dose containers, for example, sealed ampoules or vials.

Formulations suitable for sustained release parenteral administrations (e.g., biodegradable polymer formulations) are also well known in the art.  
10 See, e.g., U.S. Patent Nos. 3,773,919 and 4,767,628 and PCT Publication No. WO 94/15587.

The adrenomedullin or adrenomedullin agonist may also be administered with an bone anti-resorptive agent or another bone anabolic agent. Examples of  
15 bone anti-resorptive agents include calcitonin, bisphosphonates (e.g., etidronate, alendronate, or pamidronate), estrogen, and analogs thereof. Examples of bone anabolic agents include parathyroid hormone, parathyroid hormone related protein, cytokines (e.g.,  
20 TGF- $\beta$ , IGF-1), growth hormone, and analogs thereof.

In another aspect, the invention features a peptide consisting of between 30 and 26 amino acids and comprising the sequence adrenomedullin(27-52) wherein the carboxyl terminal is a free acid or  
25 amidated. Examples of such peptides include adrenomedullin(27-52); adrenomedullin(26-52); adrenomedullin(25-52); adrenomedullin(24-52); or adrenomedullin(23-52) wherein the carboxyl terminal is amidated. Peptides of this invention are described  
30 herein, for example, by the following format: adrenomedullin(13-52). The numbers between the parentheses refer to the number of amino acids present in the peptide, e.g., the forty amino acid fragment

between the serine residue at position 13 and the amidated tyrosine residue at position 52 of adrenomedullin. The sequence of adrenomedullin is listed in Fig. 1 of European Patent Application No.

5 622,458 A2.

The invention also includes an adrenomedullin (ADM) agonist 5-25, 6-25 or 7-25 amino acids in length. The ADM agonist comprises a fraction or the entirety of the amino acid sequence ADM(32-40). In  
10 some embodiments the ADM agonist is 9-25 amino acids in length and includes the amino acid sequence ADM(32-40), e.g., the ADM agonist can include the amino acid sequences ADM (28-40), ADM(32-52), and ADM (30-52). Other examples of ADM agonists include peptides 10-25,  
15 12-22, or 13-23 amino acids in length and containing the amino acid sequence ADM(32-40).

The ADM agonists described herein are useful in treating diseases for which increased osteoblast proliferation is desirable. Thus, the ADM agonists  
20 are useful for treating bone-associated conditions or diseases such as osteoporosis and Paget's disease and in preventing or inhibiting the development of such bone-associated diseases in subjects at risk for developing these diseases.

25 Other features and advantages of the invention will be apparent from the following description of the preferred embodiments and from the claims.

#### Detailed Description of the Invention

30 It is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent. The following specific embodiments are, therefore, to be construed



as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Also, all publications, patent applications, patents, and other references mentioned herein are incorporated by reference.

10

#### Adrenomedullin and Adrenomedullin Agonists

Adrenomedullin is a 52-amino acid having an amidated C-terminus. Many analogs, e.g., carboxyl terminal fragments, have been prepared, such as adrenomedullin(15-52), adrenomedullin(1-50), adrenomedullin(11-50), adrenomedullin(22-52), adrenomedullin(40-52), adrenomedullin(13-52), adrenomedullin(47-52), and adrenomedullin(45-52). See European Patent No. 622,458 A2; Lin, et al., Eur. J. Pharmacol. 260:1-4 (1990); and Santiago, J.A., et al., Eur. J. of Pharmacology 272:115-118 (1995). What is meant by an adrenomedullin agonist is a compound which (1) has a high affinity (e.g., a  $K_i$  of less than 1  $\mu M$ ) for the adrenomedullin receptor (as defined by the receptor binding assay described in Owji, et al., Endocrinology 136(5):2128 (1995)) and (2) promotes the proliferation of osteoblast cells (as defined below in the osteoblast proliferation assays).

### Synthesis

The synthesis of short amino acid sequences is well established in the peptide art. See, e.g., Stewart, et al., Solid Phase Peptide Synthesis (2d ed., 1984). The following is the synthesis of adrenomedullin (27-52). Other such adrenomedullin agonists can be prepared by making appropriate modifications, within the ability of someone of ordinary skill in the field of the synthetic method described herein.

Benzhydrylamine-polystyrene resin (Advanced ChemTech, Inc., Louisville, KY) (0.6 g, 0.25 mmole) in the chloride ion form was placed in the reaction vessel of an Advanced ChemTech peptide synthesizer programmed to perform the following reaction cycle: (a) methylene chloride; (b) 33% trifluoroacetic acid in methylene chloride (2 times for 1 and 15 min each); (c) methylene chloride; (d) ethanol; (e) methylene chloride; and (f) 10% diisopropylethylamine in methylene chloride.

The neutralized resin was stirred with Boc-Tyr(2,6-dichlorobenzyl) and diisopropylcarbodiimide (0.75 mmole each) in methylene chloride for 1 h and the resulting amino acid resin was then cycled through steps (a) to (f) in the above wash program. The following amino acids (0.75 mmole) were then coupled successively by the same procedure: Boc-Gly, Boc-Gln, Boc-Pro, Boc-Ser(benzyl), Boc-Ile, Boc-Lys(2-chloro-CBZ), Boc-Ser(benzyl), Boc-Arg(p-Tosyl), Boc-Pro, Boc-Ala, Boc-Ala, Boc-Val, Boc-Asn, Boc-Asp(cyclohexyl), Boc-Lys(2-chloro-CBZ), Boc-Asp(cyclohexyl), Boc-Lys(2-chloro-CBZ), Boc-Asp(cyclohexyl), Boc-Thr(benzyl), Boc-Phe, Boc-Gln, Boc-Tyr(2,6-dichlorobenzyl), Boc-

Ile, Boc-Gln, Boc-His (benzyloxymethyl), and Boc-Ala. After removal of the last Boc group and washing and drying, the completed resin weighed 1.11 g. All amino acids were purchased from Bachem California,

5 (Torrence, CA).

The resin described above (1.11 g, 0.25 mmole) was mixed with anisole (5 ml), dithiothreitol (100 mg) and anhydrous hydrogen fluoride (35 ml) at 0°C and stirred for 45 min. Excess hydrogen fluoride was  
10 evaporated rapidly under a stream of dry nitrogen, and free peptide precipitated and was washed with ether. The crude peptide was then dissolved in a minimum volume of 2 M acetic acid and eluted on a column (2.5 x 100 cm) of Sephadex G-50 (Pharmacia, Piscataway, NJ)  
15 using the same solvent. Fractions containing a major component, detected by ultraviolet absorption and thin layer chromatography, were then pooled, evaporated to a small volume, and applied to a column (2.5 x 50 cm) of Vydac octadecylsilane silica (10-15 µ; Rainin,  
20 Emeryville, CA). This column was eluted with a linear gradient of 10-45% acetonitrile in 0.1% trifluoroacetic acid in water. Fractions were examined by thin layer chromatography (tlc) and analytical high performance liquid chromatography  
25 (hplc) and pooled to give maximum purity. Repeated lyophilization of the solution from water gave the product as the amide and as a white, fluffy power. The product is found to be homogeneous by hplc and  
30 confirmed the composition of the peptide. Laser desorption mass spectroscopy gave the expected molecular weight.

In vitro studies

Adrenomedullin agonists can be tested for their ability to promote bone growth by examining their activity in the *in vitro* and *in vivo* assays described  
5 herein.

Osteoblast Cell Culture

Osteoblasts were isolated by collagenase digestion from 20-day fetal rat calvariae. The  
10 calvariae were then treated twice with phosphate buffered saline (PBS; Gibco, Grand Island, NY) containing 3 Mm ethylene diamine-acetic acid (EDTA; Sigma Chemical Co., St. Louis, MO) for 15 minutes at 37°C in a shaking water bath. After washing once in  
15 PBS, 3 ml of 1 mg/ml collagenase (Sigma Chemical Co.) was added to the calvariae for 10 minutes at 37°C. After discarding the supernatant, the calvariae were treated twice with 2 mg/ml collagenase (30 mins, 37°C). The supernatants were then centrifuged and the cells  
20 washed in Dulbecco's Modified Eagle's Medium (DMEM; Gibco Labs, Grand Island, NY) with 10% fetal calf serum (FCS), suspended in further DMEM/10% FCS, and placed in 75 cm<sup>3</sup> flasks. The cells were incubated under 5% CO<sub>2</sub> and 95% air at 37°C.

25 The osteoblast-like character of these cells has been established by demonstration of high levels of alkaline phosphatase and osteocalcin, and a sensitive adenylate cyclase response to parathyroid hormone and prostaglandins. Confluence was reached  
30 by 5-6 days, at which time the cells were subcultured. After trypsinization using trypsin-EDTA (0.05%/0.53 Nm; Gibco Labs, Grand Island, NY), the cells were rinsed in Minimal Essential Medium (MEM; Gibco Labs)

with 10% FCS and resuspended in MEM with 5% FCS, then seeded ( $10^5$  cells/ml) in 24-well plates (0.5 ml cell suspension per well, i.e.,  $5 \times 10^4$  cells/well).

5 Proliferation Assays

Cell proliferation studies (i.e., cell counts and thymidine incorporation) were performed both in actively-growing and growth-arrested cell populations. To produce actively-growing cells, subconfluent  
10 populations (24 hrs after subculturing) were changed to fresh MEM which contained 1% FCS and the test compounds. To produce growth-arrested cells, subconfluent populations were changed to serum-free medium with 0.1% bovine serum albumin plus the test  
15 compounds.

A. Cell Counts:

The effect of adrenomedullin on proliferation of fetal rat osteoblast-like cells was first assessed by the measurement of cell numbers. Cell counts were  
20 analyzed at 6, 24, and 48 hours after addition of the test compound or vehicle. The cell numbers were determined after removing cells from the wells by exposure to trypsin/EDTA (0.05%/0.53 Mm) for 5 minutes at 37°C. Counting was performed in a hemocytometer  
25 chamber. Results were expressed per well.

Treatment with adrenomedullin for 24 hours, in cultures grown in medium containing 1% FCS, produced a dose-dependent increase in actively-growing osteoblasts. A significant increase was observed at  
30 adrenomedullin concentrations of  $10^{-12}$ M and greater. This stimulation was maintained for at least 48 hours.

To determine whether proliferation in response to adrenomedullin was dependent on the basal growth

rate of the cells, these experiments were repeated in growth-arrested osteoblast preparations. The time-course of the increase in cell number in response to adrenomedullin ( $10^{-10}$ M) in these cells was similar to  
5 that seen in actively-growing cells.

Treatment for 24 hrs with the test compounds adrenomedullin(15-52), adrenomedullin(22-52), and adrenomedullin(27-52) produced similar degrees of proliferation to that of the full length  
10 adrenomedullin polypeptide.

B. DNA Synthesis:

The effect of adrenomedullin on DNA synthesis in osteoblasts was then assessed by the measurement of [ $^3$ H]-thymidine incorporation into isolated fetal rat  
15 osteoblast-like cells. [ $^3$ H]-thymidine incorporation into actively-growing and growth-arrested cells was assessed by pulsing the cells with [ $^3$ H]-thymidine (1  $\mu$ Ci/ml) (Amersham, Arlington Heights, IL) two hours before the end of the experimental incubation. The  
20 experiment was terminated at 6, 24, or 48 hours by washing the cells in MEM with cold thymidine followed by 10% trichloroacetic acid. The precipitate was washed twice with ethanol:ether (3:1), and the wells were desiccated at room temperature. The residue was  
25 redissolved in 0.5 M KOH at 85°C for 30 mins, neutralized with 1 M HCl, and an aliquot counted for radioactivity. Results were expressed as cpm per well.

Treatment with adrenomedullin ( $10^{-10}$ M) for 24  
30 hours significantly stimulated [ $^3$ H]-thymidine incorporation into both actively-growing and growth-arrested cells.

The effect of adrenomedullin fragments on proliferation of primary cultures of osteoblasts was also tested. Addition of either ADM(28-40), ADM(32-52), ADM (28-40), and ADM (27-52) to a final concentration of 1 nm produced a statistically significant increase in cell number relative to control osteoblasts. Thymidine incorporation was also increased in osteoblasts treated with 1 nm of these fragments.

10

#### Bone Organ Culture

Bone resorption studies were carried out in neonatal mouse calvariae as previously described (Reid, et al., Endocrinology 126:1416-1420 (1990)).

15 Mice were injected subcutaneously with 5  $\mu$ Ci  $^{45}\text{Ca}$  (Amersham) at 2 days of age, and hemi-calvariae were dissected out 4 days later. Hemi-calvariae were pre-incubated for 24 hours in medium 199 (Gibco BRL, Grand Island, NY) with 0.1% bovine serum albumin, then  
20 changed to fresh medium containing adrenomedullin or control vehicle. Incubation was continued for a further 48 hours. In the last 4 hours of incubation [ $^3\text{H}$ ]-thymidine was incorporated into the organ cultures as described previously (Lowe, et al., Calif. Tissue  
25 Int. 49-394-397 (1991)). There were 5-7 calvariae in each group.

There was no significant change in  $^{45}\text{Ca}$  release from prelabeled calvariae treated for 48 hours with adrenomedullin at concentrations of  $10^{-7}$  M to  $10^{-10}$  M  
30 indicating that adrenomedullin did not stimulate bone resorption. In contrast, [ $^3\text{H}$ ]-thymidine incorporation was significantly increased in the same experiments indicating that adrenomedullin stimulated bone growth.

In vivo Studies

The local effects of adrenomedullin on bone histology *in vivo* were assessed in adult mice using a previously described model (Cornish et al., Endocrinology 132:1359-1366, 1993). Sexually mature male ARC Swiss Webster mice aged between 40 and 50 days and weighing 25-35 g were given injections (25 µl) over the periosteum of the right hemicalvariae for 5 consecutive days. Previous studies with dye injections have shown that the injected material spreads over much of the injected hemicalvariae but does not cross the midline. The animals were maintained on a low calcium diet (0.1%) from 5 days prior to the first injection. Two groups of mice (n=12 in each) were injected daily with adrenomedullin in doses of  $4 \times 10^{-10}$  M and  $4 \times 10^{-9}$  M, respectively. These doses were chosen based on experience with other bone-active peptides in this model. Animals in the control group (n=16) were injected with vehicle (water) only. All animals were sacrificed 1 week following the last injection. The study had the approval of the local institutional review board.



The calvariae were dissected free of soft tissue, and gross morphology was assessed by examination of the intact calvariae under a dissection microscope. Bone tissue was fixed in 10% phosphate-buffered formalin, dehydrated in a graded series of ethanol solutions and embedded undecalcified in methyl methacrylate resin. Sections (4  $\mu$ m thick) were cut on a Leitz rotary microtome (Leica Instruments, Nussloch, Germany) using a tungsten-carbide knife, then mounted on gelatin-coated slides and air-dried. The sections were stained with a Goldner tri-chrome stain and examined using an Olympus BX 50 microscope (Olympus Optical Co Ltd, Tokyo, Japan) which was attached to an Osteomeasure Image Analyzer (Osteometrics Inc., Atlanta, GA). Histomorphometric analyzes were made of three adjacent fields (using a 20x objective) in each hemicalvaria. This results in measurements being made over >90% of the length of each hemicalvaria.

The parameters assessed are as defined by the American Society for Bone and Mineral Research (Parfitt et al. J. Bone Miner. Res. 2:595-610, (1987)), and are expressed per mm of calvarial length. Osteoblasts were defined as cells immediately adjacent to osteoid. Osteoclast numbers included only multinucleated cells. The various surface estimates were based on measurements of both periosteal and intramembranous surfaces: those eroded by osteoclasts (eroded perimeter), those immediately adjacent to osteoclasts (osteoclast perimeter), and those immediately adjacent to osteoblasts (osteoblast perimeter). The precision of these histomorphometric measurements in these studies (expressed as coefficients of variation of paired measurements) are

as follows: mineralized bone area 1.3%, osteoid area 6.9%, osteoblast perimeter 6.8%, osteoblast number 1.7%, eroded perimeter 6.7%, osteoclast perimeter 7.9%, osteoclast number <1.0%, and calvarial length 0.2%. All measurements were made by one operator who was blinded to the treatment group of each bone.

In the *in vivo* experiment, the primary end-point for each histomorphometric index was the determination of whether it was different in the injected right hemicalvaria from the contralateral, uninjected bone of the same animal. The absolute values of each histomorphometric index are presented for the injected and uninjected hemicalvariae by treatment group in Tables 1-3. The tables set out the histomorphometric indices in the uninjected and injected hemicalvariae from each of three groups: mice injected with vehicle (Table 1), mice injected with  $4 \times 10^{-10}$  M adrenomedullin (Table 2), or mice injected with  $4 \times 10^{-9}$  M adrenomedullin (Table 3). Statistical analysis performed on the ratios of each index in the injected to the uninjected halves of each calvariae revealed two- to three-fold increases in the indices of osteoblast activity in those bones exposed to either dose of adrenomedullin. Resorption indices showed slight upward trends in the presence of adrenomedullin but only for eroded perimeter was this significant. Mineralized bone area was increased by 13.6% with the higher dose of adrenomedullin. Periosteal area was not changed ( $P = 0.54$ ).

Tables 1-3. Effects of Adrenomedullin on Histomorphometric Indices in Adult Mouse Calvariae *in vivo*

Table 1

Index	Vehicle	
	Uninjected	Injected
Osteoid Area	0.0025 (0.0004)	0.0021 (0.0003)
Ob Perimeter	0.69 (0.10)	0.76 (0.07)
Number of Obs	65 (8)	68 (5)
Eroded Pm	0.74 (0.10)	0.76 (0.10)
Oc Pm	0.12 (0.01)	0.13 (0.02)
Number of Ocs	4.4 (0.3)	4.5 (0.3)
Periosteal Area	0.014 (0.002)	0.013 (0.001)
Bone Area	0.113 (0.005)	0.106 (0.005)

Table 2

Index	Adrenomedullin $4 \times 10^{-10}$ mol	
	Uninjected	Injected
Osteoid Area	0.0016 (0.0003)	0.0041 (0.0005)
Ob Perimeter	0.72 (0.10)	1.21 (0.13)
Number of Obs	57 (5)	111 (11)
Eroded Pm	0.77 (0.13)	0.85 (0.09)
Oc Pm	0.12 (0.02)	0.14 (0.01)
Number of Ocs	4.4 (0.4)	5.2 (0.3)
Periosteal Area	0.013 (0.002)	0.015 (0.001)
Bone Area	0.115 (0.005)	0.122 (0.006)

Table 3

Index	Adrenomedullin $4 \times 10^{-9}$ mol	
	Uninjected	Injected
Osteoid Area	0.0012 (0.0002)	0.0032 (0.0008)
Ob Perimeter	0.56 (0.06)	1.33 (0.09)
Number of Obs	61 (5)	105 (6)
Eroded Pm	0.67 (0.08)	0.67 (0.07)
Oc Pm	0.12 (0.01)	0.15 (0.01)
Number of Ocs	4.4 (0.3)	5.0 (0.3)
Periosteal Area	0.011 (0.001)	0.012 (0.002)
Bone Area	0.114 (0.006)	0.128 (0.007)

\*Data are mean (se). Ob, osteoblast; Pm, perimeter; Oc, osteoclast

5

#### Other Embodiments

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, that the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. For example, the adrenomedullin agonists described herein may include amino acids linked via non-peptidyl linkages, e.g., a peptide in which one or more peptide bonds have a carbonyl oxygen replaced with a methylene group. The adrenomedullin agonists may alternatively or in addition include amino acids other than the encoded amino acids. These include, e.g., substitution of the naturally occurring L-form of an encoded amino acid with its corresponding D-form. Other aspects, advantages, and modifications are within the claims.

Claims:

1. An adrenomedullin (ADM) agonist 7-25 amino acids in length, wherein said ADM agonist comprises a  
5 fraction or the entirety of the amino acid sequence ADM(32-40).

2. The ADM agonist of claim 1, wherein said ADM agonist is 9-25 amino acids in length and  
10 comprises the amino acid sequence ADM(32-40).

3. The ADM agonist of claim 1, wherein the carboxyl terminus is amidated.

15 4. The ADM agonist of claim 2, wherein the carboxyl terminus is amidated.

5. The ADM agonist of claim 2, wherein said ADM agonist comprises the amino acid sequence ADM(28-  
20 40).

6. The ADM agonist of claim 2, wherein said ADM agonist comprises the amino acid sequence ADM (29-  
40).

25 7. The ADM agonist of claim 2, wherein said ADM agonist comprises the amino acid sequence ADM(32-52).

30 8. The ADM agonist of claim 2, wherein said ADMagonist comprises the amino acid sequence ADM(30-52).

9. A pharmaceutical composition comprising the ADM agonist of claim 1 or 2.

5 10. A method of promoting bone growth in a patient, said method comprising administering to a patient in need thereof an ADM agonist 7-25 amino acids in length, wherein said ADM agonist comprises a fraction or the entirety of the amino acid sequence ADM(32-40).

10

11. The method of claim 10, wherein said agonist is 9-25 amino acids in length and comprises the amino acid sequence ADM(32-40).

15

12. The method of claim 10, wherein said ADM agonist is administered nasally or pulmonarily.

20

13. The method of claim 10, wherein said ADM agonist is in a sustained release formulation.

14. The method of claim 10, wherein said ADM agonist is administered parenterally.

25

15. The method of claim 10, wherein said ADM agonist is amidated at its carboxyl terminus.

16. The method of claim 10, wherein said patient suffers from osteoporosis.

30

17. The method of claim 11, wherein said patient suffers from osteoporosis.

18. A method of promoting bone growth in a subject at risk for developing a bone-associated disease, said method comprising administering to a subject in need thereof an ADM agonist 7-25 amino acids in length, wherein said ADM agonist comprises a fraction or the entirety of the amino acid sequence ADM(32-40).

19. The method of claim 18, wherein said ADM agonist is 9-25 amino acids in length and includes the amino acid sequence ADM(32-40).

20. The method of claim 18, wherein said ADM agonist is administered nasally or pulmonarily.

21. The method of claim 18, wherein said ADM agonist is in a sustained release formulation.

22. The method of claim 18, wherein said ADM agonist is administered parenterally.

23. The method of claim 18, wherein said ADM agonist is amidated at its carboxyl terminus.

24. The method of claim 18, wherein said subject is at risk for osteoporosis.

25. The method of claim 19, wherein said subject is at risk for osteoporosis.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/NZ00/00038

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>												
Int. Cl. <sup>7</sup> : C07K 7/06, 7/08, 14/575; A61K 38/08, 38/10, 38/22; A61P 19/08, 19/10												
According to International Patent Classification (IPC) or to both national classification and IPC												
<b>B. FIELDS SEARCHED</b>												
Minimum documentation searched (classification system followed by classification symbols) IPC: A61K, C07K AND KEYWORDS AS INDICATED BELOW												
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched AU: IPC AS ABOVE												
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Derwent, CA, Medline: sequence search, ADM, adrenomedullin, bone, osteo?, Paget's												
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>												
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.										
A	Critical Reviews in Neurobiology, (1997) 11 (2-3), (WIMALAWANSA, S.J. et al.), "Amylin, Calcitonin Gene-Related Peptide, Calcitonin, and Adrenomedullin: A Peptide Superfamily" pages 167-239 Entire document	1-25										
A	American Physiological Society, (1997), 273 (6, Pt. 1), (CORNISH, J. et al), "Adrenomedullin is a potent stimulator of osteoblastic activity in vitro and in vivo" pages E1113-E1120 Entire document	1-25										
A	EP 622 458 A (SHIONOGI & CO. LTD.) 2 November 1994 Entire document	1-25										
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex												
<p>* Special categories of cited documents:</p> <table border="0"> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E" earlier application or patent but published on or after the international filing date</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td>"&amp;" document member of the same patent family</td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	"P" document published prior to the international filing date but later than the priority date claimed	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention											
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone											
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art											
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family											
"P" document published prior to the international filing date but later than the priority date claimed												
Date of the actual completion of the international search 9 August 2000		Date of mailing of the international search report 1 SEP 2000										
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustalia.gov.au Facsimile No. (02) 6285 3929		Authorized officer  N.E. HOWARD Telephone No : (02) 6283 2245										



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/NZ00/00038

**C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97/38704 A (AUCKLAND UNISERVICES LIMITED) 23 October 1997 See page 6, lines 18-34 and claims	1-25
A,P	WO 99/16406 A (AUCKLAND UNISERVICES LIMITED) 8 April 1999 Entire document	1-25

### Information on patent family members

International application No.  
PCT/NZ 00/00038

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member (To put a line under the citations tab to the first point on the next row and press F8)					
EP	622458	AU	60648/94	CA	2122112	JP	7-196693
		US	5639855	US	5830703	US	5837823
		US	5910416	JP	2-774769		
WO	97/38704	AU	26730/97	CA	2252228	EP	904094
		US	5888963				
WO	99/16406	AU	93690/98	EP	1027027		